AKT1 and neoplasm: Pyrotinib can inhibit the formation of homologous/heterodimer and auto-phosphorylation of HER family by covalently binding with ATP at intracellular kinase regions, block the activation of downstream signaling pathways (RAS/RAF/MEK/MAPK and PI3K/AKT) and tumor cell cycle in G1 phase, and restrict tumor development [12,13].